Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas ...

Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it agreed to a $90 million settlement with Japan's Astellas Pharma ...

In a statement, Japan's Astellas said the specific terms of the settlement were confidential; however, a regulatory filing ...

Lupin resolves patent dispute with Astellas, agreeing to pay $90 million to continue selling Mirabegron for overactive ...

The agreement brings an end to Lupin’s pending litigation with Astellas, disclosed earlier in April 2025, and allows the company to continue selling Mirabegron in the US.

Under the agreement, Lupin and its U.S. unit will pay Astellas a USD 75 million upfront payment and per-unit licensing fees ...

Pharmaceutical company Lupin has settled a patent infringement dispute with Astellas Pharma for $90 million, allowing continued sale of its Mirabegron product.

According to an exchange filing, Lupin and its U.S. subsidiary will pay Astellas a total of $90 million. This includes a $75 million prepaid option payment and an undisclosed per-unit license fee on ...

Lupin said on Tuesday it agreed to a $90-million settlement with Japan's Astellas Pharma in a patent dispute over the bladder disorder drug Mirabegron, a move that allows it to continue selling the pr ...

G_older_woman_urinary_incontinence Phase 4 trial showed that mirabegron significantly decreased incontinence episodes and micturitions compared with placebo among patients aged 65 years and older.

Review the side-effects of Mirabegron as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Lupin resolves patent dispute with Astellas, securing continued Mirabegron sales in the US with a $90 million settlement.